SubHero Banner
Text

Vabysmo(faricimab-svoa) – New drug approval

January 28, 2022 - Genentech announced the FDA approval of Vabysmo (faricimab-svoa), for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Download PDF